001 vs placebo), compared to an increase of 5. Patients also
experienced sizeable improvements in their lipid and glycemic profiles," said
Luc Van Gaal, M.0% and 7. Only in a very small
number of cases did these side effects lead to discontinuation of drug use. The publication concludes that the 1-year study results show
that rimonabant produced clinically meaningful weight loss, reduction in waist
circumference and associated improvements in several metabolic and
cardiovascular risk factors and holds therapeutic promise.

(iii) Ford et al, Increasing Prevalence of the Metabolic Syndrome Among
US Adults. TSX: TMC

TORONTO, June 28 - Tm Bioscience Corporation
(Toronto, Ontario; TSX: TMC), a leader in the commercial genetic testing
market, today announced it has signed a master purchase agreement to supply
Laboratory Corporation of America(R ) Holdings (LabCorp(R); NYSE: LH) with a
suite of Tag-It(TM) products."
The first products covered under the agreement are Tag-It(TM) ASR(x)
reagents for use in LabCorp's Ashkenazi Jewish Panel (AJP) gene assay, a
single genetic test that combines mutation detection for eight disease states
into one assay. The performance characteristics of
these products have not been established

About Tm Bioscience - Putting the Human Genome to Work(TM)
Tm Bioscience is a DNA-based diagnostics company developing a suite of
genetic tests.tmbioscience.

tricuspid tietze

The percentage of patients fulfilling the criteria for the metabolic
syndrome was reduced by 54% after treatment with rimonabant 20 mg compared to
21% treated with placebo (p < 0.8% in patients treated with rimonabant
20 mg (p < 0.03 mmol/L in the placebo-treated group. After a screening period of two weeks, patients were
prescribed a mild hypocaloric diet (designed to reduce daily caloric intake by
600 kcal from the patients' energy requirements) and entered a four-week
placebo run-in period.

treacher tinea

94 inches for those on placebo.8 micron
IU/mL in the placebo-treated group.002 vs placebo) compared with an increase of 0. The study was conducted in 60 centres across Europe and the United
States for a period of 2 years. We are delighted to begin
supplying LabCorp and look forward to working with them as they launch
additional Tag-It(TM) products.

tricuspid torticollis

55 lbs (p < 0.001 vs placebo) compared to 7.2% of patients in the rimonabant
5 mg/day group (p = 0. placebo was also observed. Almost 50% of the
rimonabant -induced changes in HDL-cholesterol and triglycerides were
independent of the weight loss observed , suggesting a direct effect of the
drug on lipid metabolism.
The RIO-Europe findings also showed rimonabant was well tolerated. All genetic tests from Tm
Bioscience are based on the Tag-It (TM) Universal Array platform, which
utilizes a proprietary universal tag system that allows for easy optimization,
product development and expansion.

trachoma tinea

Moreover, 39% (p < 0.

com.

bucy tyrosinemia

Reducing abdominal fat is a recognized priority for reducing the risk of
CVD(iii).3% in
rimonabant 5 mg and placebo groups, respectively.
RIO-Europe, an international, multicentre, randomized, double -blind,
placebo-controlled, parallel-group study, compared rimonabant 20 mg/day and
5 mg/day to placebo in 1,507 overweight/obese patients (Body Mass Index (BMI)
greater than or equal to 33 kg /square meter or BMI > 27 kg/square meter with
co-morbidities such as treated or untreated dyslipidemia and/or treated or
untreated hypertension).
RIO-Europe is one of four phase III studies comprising the RIO program, to
assess the efficacy and safety of rimonabant in weight reduction and metabolic
risk factor improvement in over 6,600 overweight or obese patients.

thromboangiitis tinea

001 vs placebo) and 30.3% (p < 0.09 mmol/L was seen
in patients treated with rimonabant 20 mg (p = 0., Professor of Diabetology , Metabolism and Clinical
Nutrition, University Hospital Antwerp, Belgium, Principal Investigator of the
RIO-Europe trial. population, providing us with an extensive
customer base for our current and future products. Analytical and performance characteristics
are not established. Tm Bioscience's product pipeline includes tests for genetic
disorders, drug metabolism, and infectious diseases.

thrombocytopenia tricuspid

Among patients completing the study, 67.4% of patients treated with
rimonabant 20 mg/day lost more than 5% of their initial body weight
(p < 0.001 vs placebo) of patients on rimonabant 20 mg/day lost
more than 10% of their initial body weight compared to 15.D.

torticollis trematodes

001 vs placebo), compared to 44. According to the ATP III definition,
metabolic syndrome includes at least 3 of the following criteria:
abdominal obesity: waist circumference Men >102 cm (40 inches),
Women > 88 cm (35 inches); hypertension: >130/85 mmHg;
hypertriglyceridemia: >150 mg/ dL; Low HDL cholesterol: Men <40 mg/
dL, Women <50 mg/ dL; Abnormal fasting glucose: greater than 110 mg/
dL.
"LabCorp is one of the foremost providers of diagnostic testing in the
U.
(xx) For Investigational Use Only.

staphylococcal treacher

1st Year Results of Rio-Europe Study Published in The Lancet

A significant reduction in fasting plasma glucose of 0. "What is particularly noteworthy in the study findings is
the effect rimonabant 20 mg had on metabolic and cardiovascular risk factors,
which is partly independent of weight loss," he added. Side
effects were mainly mild and transient and most frequently involved nausea
(4. Afterwards, patients were randomly assigned to one of
the three treatment groups: rimonabant 20 mg or 5 mg or placebo for 104 weeks
of double -blind treatment using a randomization ratio of 2:2:1.

About Tag-It(TM) reagents and genetic tests
Tm Bioscience's product menu is focused in the fields of human genetic
disorders, pharmacogenetics and infectious disease.

tricuspid torticollis

The
trial findings also revealed a decrease in the number of patients with
metabolic syndrome(i) in the rimonabant 20 mg/day group. Triglycerides were reduced by 6.4% in the
placebo-treated group. At each visit
patients received dietary counseling and were encouraged to increase physical
activity.

(i) Metabolic Syndrome is a term that encompasses a series of health
risks or conditions that increase a person's chance to develop heart
disease, stroke and diabetes.

typhus thromboangiitis

54 inches for those on
rimonabant 5 mg (p = 0.005) in the rimonabant 5 mg/day group and 13.3%, 5.

(ii) Yusuf et al, Effect of potentially modifiable risk factors
associated with myocardial infarction in 52 countries (the
INTERHEART study ): case-control study. The Company has
commercialized Analyte Specific Reagents(x) and a series of Tag-It(TM)
tests(xx) for a variety of genetic disorders. Assays from Tm operate on the Luminex
xMAP (R) system, a well-established bead based instrument.

typhus epidermal

3% of those on
rimonabant 5 mg/day and 12.7% for placebo,
rimonabant 5 mg and rimonabant 20 mg respectively). The two-year data
were reported recently at the 2005 annual scientific session of the American
College of Cardiology in Orlando, Florida. and now one of our largest customers," said Greg Hines, President and CEO
of Tm Bioscience . Food and Drug Administration (FDA) as an in vitro device
(IVD) for diagnostic use in the United States.

toxoplasmosis takatsuki

The Company's Tag-It(TM) Cystic
Fibrosis (CF) Kit is the first multiplexed human disease genotyping test to be
cleared by the U.

bucy tuberous

Obesity is a major public health burden and a key risk factor for
the development of cardiovascular disease(ii).7% and 8.9% for placebo, rimonabant 5 mg and rimonabant 20 mg
respectively), diarrhea (3.

Tm Bioscience to supply LabCorp with Tag-It(TM) products

staphylococcal epidermal

Published report of study concludes rimonabant holds therapeutic promise in
improving several cardiovascular and metabolic risk factors

ANTWERP, Belgium, The first year results of the
two-year trial Rimonabant In Obesity -- Europe (RIO-Europe), a Phase III
clinical study comparing rimonabant, the first agent in a new therapeutic
class known as selective cannabinoid type 1 (CB1) blockers, to placebo , were
published today in The Lancet. The one-year results of the RIO-Europe study confirm rimonabant 's
potential to become an important tool in the reduction of multiple
cardiovascular risk factors by lowering body weight and improving metabolic
syndrome-associated parameters in overweight or obese subjects.5 lbs for patients on
rimonabant 5 mg/day (p = 0.001) versus 1.001 vs placebo), compared to
16.S.

tinea tietze

2% for placebo, rimonabant 5 mg and
rimonabant 20 mg respectively) and dizziness (4.
The improvements in metabolic and cardiovascular risk factors in patients
receiving rimonabant 20 mg/day are beyond those expected through weight
reduction alone. The Lancet, Volume 364 Number
9438, September 11-17, 2004. Additional information about Tm Bioscience can be found
at http://www.

typhus tabes

The reported findings in overweight or obese
patients taking rimonabant 20 mg once daily show a significant reduction in
body weight, waist circumference -- a marker of intra-abdominal adiposity --
as well as improvements in insulin resistance and lipid and glucose profiles.2% (p = 0. Not only have we seen a reduction in body
weight, but patients were also able to achieve significant reduction in waist
circumference, a measure of dangerous intra-abdominal adiposity.0%, 6. Combined, the
Universal Array and Luminex instrument enable the rapid production of
flexible, high-throughput, low-cost DNA -based tests.

torticollis toxoplasmosis

Obesity is typically measured
by body mass index (BMI); however, recent findings have shown that abdominal
obesity is a much better predictor of heart attack than weight or BMI(ii).
At one year, patients treated with rimonabant 20 mg/day lost an average of
14.001).0 micron IU /mL in the
rimonabant 20 mg group (p < 0.

(x) Analyte Specific Reagent.

multiforme epidermal

002 vs placebo ) and 3.56 inches (p < 0. In patients
treated for one year with rimonabant 20 mg/day, HDL-cholesterol
(good cholesterol) increased by 22.026 vs placebo) compared with
an increase of 0. A similar pattern was
observed for insulin levels which decreased by 1.
"The RIO-Europe 1-year trial results indicate that patients treated with
rimonabant 20 mg/day experienced improvements across a broad range of
cardiovascular risk factors.9%, 7.S. The AJP assay detects gene mutations associated with Tay-Sachs
disease, Canavan Disease, Familial Dysautonomia, Gaucher Disease, Bloom
Syndrome, Fanconi Anemia, Neimann-Pick Disease, and Mucolipidosis Type IV. Tm Bioscience is located
in Toronto, Ontario .

dorsalis thrombocytopenia

1% and 12.

treacher thrombocytopenia

Despite advances in the management of cardiovascular disease (CVD) in
recent decades , CVD nonetheless remains the leading cause of mortality
worldwide.97 lbs for those on placebo.5% in the placebo group.001 vs placebo) versus an increase of 1.3% in HOMA-IR
(a measure of insulin resistance) was seen in the rimonabant 20 mg group
(p = 0.

thromboangiitis typhus

002 vs placebo) and 0.4% of those on placebo . In addition to the reduction in weight
and waist circumference, a statistically significant improvement in metabolic
risk factors with rimonabant 20 mg vs.4% in the placebo
group. Finally, a decrease of 0.0%, 8. The
one-year results of the RIO-Europe study were first released at the European
Society of Cardiology congress in Munich in September 2004. "With this supply agreement, our commercial footprint
reaches the majority of the U.S.

tabes typhus

Patients on rimonabant 20 mg/day also had an average decrease in their waist
circumference of 2.

torticollis toxoplasmosis

The improvement in lipids (HDL-cholesterol and triglycerides ) was shown to be
partially independent from weight loss, suggesting a direct effect of
rimonabant on these important metabolic cardiovascular risk parameters. Diabetes Care, Vol 27, Number 10, October 2004.

thromboangiitis tyrosinemia